2017 FROGG Workshop
30 March - 1 April
With the increasing use of ultrasensitive PSA surveillance after definitive treatment for prostate cancer, biochemical failure is recognised at an earlier time and opportunities to intervene are appearing, including stereotactic body radiotherapy for oligometastases. Worldwide knowledge, expertise and availability of PSMA scanning is becoming increasingly relevant.
This Workshop will focus on the definitions of biochemical failure as well as the assessment and potential treatment of patients judged to be suffering from it.